- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Panel Votes to Expand Use of Pneumococcal Vaccine to Adults
An FDA advisory committee has voted 14-1 in favor of expanding the indication for the pneumococcal 13-valent conjugate vaccine (Prevnar 13) to include use in adults 50 and older.
Currently the vaccine is approved only for use in children.
The FDA's Vaccines and Related Biologics Advisory Committee voted for accelerated approval, reserved for biologics or drugs that are intended to treat serious or life-threatening illnesses and that provide a meaningful benefit over existing treatments.
Read the full story at: http://www.medpagetoday.com/InfectiousDisease/Vaccines/29755
Source: MedPage Today
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
